KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Account Payables (2017 - 2019)

Alnylam Pharmaceuticals' Change in Account Payables history spans 11 years, with the latest figure at -$30.1 million for Q3 2019.

  • For Q3 2019, Change in Account Payables fell 431.18% year-over-year to -$30.1 million; the TTM value through Sep 2019 reached $12.4 million, up 6.22%, while the annual FY2018 figure was $15.5 million, 413.38% up from the prior year.
  • Change in Account Payables reached -$30.1 million in Q3 2019 per ALNY's latest filing, down from $43.5 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $43.5 million in Q2 2019 to a low of -$30.1 million in Q3 2019.
  • Average Change in Account Payables over 5 years is $552687.5, with a median of $328500.0 recorded in 2015.
  • Peak YoY movement for Change in Account Payables: crashed 3289.34% in 2017, then soared 6377.34% in 2019.
  • A 5-year view of Change in Account Payables shows it stood at $2.6 million in 2015, then crashed by 86.45% to $347000.0 in 2016, then soared by 3453.89% to $12.3 million in 2017, then surged by 30.78% to $16.1 million in 2018, then tumbled by 286.56% to -$30.1 million in 2019.
  • Per Business Quant, the three most recent readings for ALNY's Change in Account Payables are -$30.1 million (Q3 2019), $43.5 million (Q2 2019), and -$17.1 million (Q1 2019).